Concepedia

Phase II, Open-label, Single-arm, Multicenter Study to Assess the Activity and Safety of Alectinib as Neoadjuvant Treatment in Surgically Resectable Stage III ALK-positive NSCLC: ALNEO Trial

Alessandro Leonetti, Roberta Minari, Luca Boni, Letizia Gnetti, Michela Verzè, Luigi Ventura, L Musini, Michele Tognetto, Marcello Tiseo

Clinical Lung Cancer · 2021 · 59 citations · 9 references

DOI

Concepts

References

9

Alectinib versus Crizotinib in Untreated <i>ALK</i>-Positive Non–Small-Cell Lung Cancer

Solange Peters, D. Ross Camidge, Alice T. Shaw et al. · New England Journal of Medicine · 2017 · 2.4K citations · Full text

Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial

Mariano Provencio, Ernest Nadal, Amelia Insa et al. · The Lancet Oncology · 2020 · 788 citations

, , +4

Erlotinib Versus Gemcitabine Plus Cisplatin as Neoadjuvant Treatment of Stage IIIA-N2 <i>EGFR</i>-Mutant Non–Small-Cell Lung Cancer (EMERGING-CTONG 1103): A Randomized Phase II Study

Wen‐Zhao Zhong, Ke‐Neng Chen, Chun Chen et al. · Journal of Clinical Oncology · 2019 · 259 citations

Osimertinib as adjuvant therapy in patients (pts) with stage IB–IIIA EGFR mutation positive (EGFRm) NSCLC after complete tumor resection: ADAURA.

Roy S. Herbst, Masahiro Tsuboi, Thomas John et al. · Journal of Clinical Oncology · 2020 · 96 citations

, , +17

Neoadjuvant Crizotinib in Resectable Locally Advanced Non–Small Cell Lung Cancer with ALK Rearrangement

Chao Zhang, Shaolei Li, Qiang Nie et al. · Journal of Thoracic Oncology · 2018 · 94 citations · Full text

, , +8